Genetic Signatures Limited Share Price
Equities
GSS
AU000000GSS4
Advanced Medical Equipment & Technology
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.68 AUD | -2.16% | 0.00% | +56.32% |
04-30 | Genetic Signatures Appoints Interim CEO | MT |
04-28 | Genetic Signatures' Sales Drop in Fiscal Q3 | MT |
Sales 2024 * | 10.1M 6.53M 524M | Sales 2025 * | 26.2M 16.94M 1.36B | Capitalization | 130M 83.8M 6.72B |
---|---|---|---|---|---|
Net income 2024 * | -17M -10.99M -881M | Net income 2025 * | -6M -3.88M -311M | EV / Sales 2024 * | 10.9 x |
Net cash position 2024 * | 20M 12.93M 1.04B | Net cash position 2025 * | 7M 4.53M 363M | EV / Sales 2025 * | 4.68 x |
P/E ratio 2024 * |
-7.39
x | P/E ratio 2025 * |
-19.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.08% |
1 day | -2.16% | ||
1 month | +0.74% | ||
3 months | +38.78% | ||
6 months | +36.00% | ||
Current year | +56.32% |
Managers | Title | Age | Since |
---|---|---|---|
John Melki
CEO | Chief Executive Officer | - | 31/12/02 |
Karl Pechmann
DFI | Director of Finance/CFO | - | 25/06/23 |
Douglas Millar
CTO | Chief Tech/Sci/R&D Officer | - | 14/02/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Anthony Radford
BRD | Director/Board Member | - | 14/09/15 |
Caroline Waldron
BRD | Director/Board Member | - | 12/05/22 |
Michael Aicher
BRD | Director/Board Member | 64 | 01/01/14 |
Date | Price | Change | Volume |
---|---|---|---|
01/05/24 | 0.68 | -2.16% | 1 662 |
30/04/24 | 0.695 | -0.71% | 107,446 |
29/04/24 | 0.7 | +2.19% | 96,719 |
26/04/24 | 0.685 | +0.74% | 71,242 |
24/04/24 | 0.68 | 0.00% | 75,859 |
Delayed Quote Australian S.E., May 01, 2024 at 04:54 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.32% | 85.63M | |
+7.15% | 220B | |
+6.60% | 183B | |
+9.86% | 133B | |
+24.32% | 107B | |
-0.95% | 63.05B | |
+11.04% | 51.74B | |
+4.81% | 50.47B | |
-1.43% | 40.91B | |
+24.40% | 31.91B |
- Stock Market
- Equities
- GSS Stock